Labitad, Espiridion N.

HRN: 27-37-40  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/30/2025
CEFTRIAXONE 1G (VIAL)
06/30/2025
07/06/2025
IV
2g
Od
Cholecystitis
Pending Pharmacy Acceptance 

 Indication:  Empiric    Type of Infection:  Intra-abdominal    Compliance to guidelines: